Abu Dhabi’s G42 Healthcare and pharmaceutical giant AstraZeneca will collaborate on clinical research and diagnostics, according to a statement from the companies Tuesday.
As part of this collaboration, G42 Healthcare and AstraZeneca will work closely together to explore real-world evidence and conduct clinical trials through IROS – the first-of-its-kind Contract Research Organisation (CRO) in the UAE.
In October, the Abu Dhabi Department of Health (DoH) and AstraZeneca signed a declaration of collaboration to boost innovation in the UAE healthcare sector by addressing the government’s strategy to increase patients’ access to quality healthcare services and treatments locally and beyond.
“AstraZeneca is excited to collaborate with G42 Healthcare to further advance the healthcare sector in the country and region. Innovation in healthcare is a continuous process, and we are constantly pushing the boundaries of science to uncover and deliver life-changing medicines to patients in the UAE and across the region. This collaboration allows us to explore greater possibilities in clinical research and diagnostics which will help us create a more patient-centric healthcare sector in the UAE,” Sameh Elfangary, country president, GCC and Pakistan at AstraZeneca said.
Both organisations will also explore real-world evidence in the field of genomics and comprehensive clinical diagnostic services through Biogenix Labs, a G42 Healthcare company that has been one of the key players in the UAE for COVID-19 testing with the other offering of products and services in the consumer and clinical health spectrum.
“Our partnership with important companies contribute to strengthen Abu Dhabi’s position as an incubator for innovation in life sciences and a leading destination for healthcare globally… This will further stimulate a knowledge-based economy in the capital and the UAE as a whole and ensure the health and safety of all communities around the world,” said Abdulla Bin Mohamed Al Hamed, Chairman of DoH.
Follow us on
